KRAS and non-small cell lung carcinoma: The results of the NSCLC part published in 2021 indicated that in PD-L1-positive, KRAS-mutated, previously untreated non-squamous stage IV NSCLC patients [113], the incidence of transaminase elevation and pneumonia (n = 8 each; 32.0%) within combined therapy was higher than that previously reported for the use of these two drugs alone, and its efficacy (the median PFS was 7.6 months (95% CI: 1.6–not estimable), the median OS was 27.8 months (95% CI: 9.9–not estimable)) was basically equivalent to that of single-agent immunotherapy [116,117].